The Impact of the Availability of Immunotherapy on Patterns of Care in Stage III NSCLC: A Dutch Multicenter Analysis

The Impact of the Availability of Immunotherapy on Patterns of Care in Stage III NSCLC: A Dutch Multicenter Analysis

Introduction: Treatment patterns in stage III NSCLC can vary considerably between countries. The PACIFIC trial reported improvements in progression-free and overall survival with adjuvant durvalumab after concurrent chemoradiotherapy (CCRT). We studied treatment decision-making by three Dutch region...

Full description

Bibliographic Details
Main Authors: Merle I. Ronden, MD, Idris Bahce, MD, PhD, Niels J.M. Claessens, MD, Nicole Barlo, MD, Max R. Dahele, MD, PhD, Johannes M.A. Daniels, MD, PhD, Caroline Tissing-Tan, MD, Edo Hekma, MD, Sayed M.S. Hashemi, MD, Antoinet van der Wel, MD, Femke O.B. Spoelstra, MD, PhD, Wilko F.A. R. Verbakel, MD, PhD, Marian A. Tiemessen, MD, Marjolein van Laren, MD, Annemarie Becker, MD, PhD, Svitlana Tarasevych, MD, Cornelis J.A. Haasbeek, MD, PhD, Karen Maassen van den Brink, MD, Chris Dickhoff, MD, PhD, Suresh Senan, MRCP, FRCR, PhD
Format: Article
Language:English
Published: Elsevier 2021-07-01
Series:JTO Clinical and Research Reports
Subjects:
Non–small cell lung cancer (NSCLC)
Stage III
Multidisciplinary tumor board (MDT)
Patterns of care
Immunotherapy
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364321000540

Internet

http://www.sciencedirect.com/science/article/pii/S2666364321000540

Similar Items